Answers are grounded in this paper and cite their sources.
Background: Warfarin is a common anticoagulant drug that has a narrow therapeutic index; higher dose causes excessive bleeding and lower dose leads to cerebrovascular clotting and stroke in patients. Genetic factors that have been associated with warfarin response are the genes of cytochrome P450 2C9 (CYP2C9), which metabolize the more active S-enantiomer of warfarin, and vitamin K epoxide reductase (VKOR), the target site for warfarin. The present study was conducted to investigate the association between CYP2C9*2, CYP2C9*3 and VKORC1 (-1639 G>A) polymorphisms with warfarin daily dose on 118 Iranian patients under warfarin treatment.
No takes yet. Share an insight, caveat, or question.
Kameli et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: